This phase 1b open-label study assesses the efficacy and safety of avelumab, an anti–programmed death ligand 1 agent, in a cohort of patients with previously treated recurrent or refractory ovarian cancer.
http://bit.ly/2RNTznl
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Summary Insulinomas are rare neuroendocrine tumours that classically present with fasting hypoglycaemia. This case report discusses an un...
-
The online platform for Taylor & Francis Online content New for Canadian Journal of Remote Sen...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου